Biogen Inc (BIIB)
192.10
-3.05
(-1.56%)
USD |
NASDAQ |
Apr 17, 16:00
192.44
+0.34
(+0.18%)
After-Hours: 07:03
Biogen Cash from Investing (TTM): -4.101B for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.101B |
| September 30, 2023 | -3.590B |
| June 30, 2023 | -175.40M |
| March 31, 2023 | 1.272B |
| December 31, 2022 | 1.577B |
| September 30, 2022 | 1.605B |
| June 30, 2022 | -300.80M |
| March 31, 2022 | -1.147B |
| December 31, 2021 | -563.70M |
| September 30, 2021 | -617.40M |
| June 30, 2021 | -436.20M |
| March 31, 2021 | -1.116B |
| December 31, 2020 | -608.60M |
| September 30, 2020 | 266.20M |
| June 30, 2020 | -47.30M |
| March 31, 2020 | 674.60M |
| December 31, 2019 | 470.50M |
| September 30, 2019 | -1.863B |
| June 30, 2019 | -2.116B |
| March 31, 2019 | -3.154B |
| December 31, 2018 | -2.046B |
| September 30, 2018 | -1.190B |
| June 30, 2018 | -1.818B |
| March 31, 2018 | -872.30M |
| December 31, 2017 | -2.963B |
| Date | Value |
|---|---|
| September 30, 2017 | -2.775B |
| June 30, 2017 | -1.492B |
| March 31, 2017 | -2.026B |
| December 31, 2016 | -2.485B |
| September 30, 2016 | -3.711B |
| June 30, 2016 | -4.737B |
| March 31, 2016 | -5.254B |
| December 31, 2015 | -4.554B |
| September 30, 2015 | -3.124B |
| June 30, 2015 | -2.675B |
| March 31, 2015 | -2.052B |
| December 31, 2014 | -1.543B |
| September 30, 2014 | -1.875B |
| June 30, 2014 | -1.659B |
| March 31, 2014 | -1.755B |
| December 31, 2013 | -1.605B |
| September 30, 2013 | -1.270B |
| June 30, 2013 | -1.468B |
| March 31, 2013 | -795.02M |
| December 31, 2012 | -950.34M |
| September 30, 2012 | -964.42M |
| June 30, 2012 | -1.029B |
| March 31, 2012 | -1.523B |
| December 31, 2011 | -1.650B |
| September 30, 2011 | -1.779B |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-4.101B
Minimum
Dec 2023
1.605B
Maximum
Sep 2022
-569.39M
Average
-436.20M
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
| Eli Lilly and Co | -7.153B |
| Bristol-Myers Squibb Co | -2.295B |
| AbbVie Inc | -2.009B |
| Amgen Inc | -26.20B |
| Regeneron Pharmaceuticals Inc | -3.185B |